Drugs / HER2Bi-Armed T Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02662348 | Feb 2016 → Nov 2017 | esophageal cancer, gallbladder cancer, gastric cancer, intestinal cancer +2 | Yi Miao | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2Bi-Armed T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02662348 ↗ |
| Modality | Cell therapy | “Expanded autologues T cells that have been coated with bi-specific antibodies, such as anti-CD3 and anti-human epidermal growth factor receptor 2 (HER2)” NCT02662348 ↗ |
| Route | Intravenous | “Patients receive HER2Bi armed T cells IV weekly for 4 weeks.” NCT02662348 ↗ |